2025 annual financial data
Corcept Therapeutics 2025 Operating margin
Corcept Therapeutics 2025 operating margin with verified reported values.
Direct answer
Operating margin was 5.88%.
Operating income was 44,797,000 USD and net income was 99,652,000 USD.
Operating cash flow was 141,996,000 USD.
Get free Corcept Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 761,407,000 USD
- Operating income
- 44,797,000 USD
- Net income
- 99,652,000 USD
- Operating cash flow
- 141,996,000 USD